

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization

Edwin H. Kim, MD,^a J. Andrew Bird, MD,^a Michael Kulis, PhD,^a Susan Laubach, MD,^a Laurent Pons, PhD,^a Wayne Shreffler, MD, PhD,^b Pamela Steele, CPNP,^a Janet Kamilaris, RN,^a Brian Vickery, MD,^a and A. Wesley Burks, MD^a *Durham, NC, and Boston, Mass*

Background: There are no treatments currently available for peanut allergy. Sublingual immunotherapy (SLIT) is a novel approach to the treatment of peanut allergy.

Objective: We sought to investigate the safety, clinical effectiveness, and immunologic changes with SLIT in children with peanut allergy.

Methods: In this double-blind, placebo-controlled study subjects underwent 6 months of dose escalation and 6 months of maintenance dosing followed by a double-blind, placebo-controlled food challenge.

Results: Eighteen children aged 1 to 11 years completed 12 months of dosing and the food challenge. Dosing side effects were primarily oropharyngeal and uncommonly required treatment. During the double-blind, placebo-controlled food challenge, the treatment group safely ingested 20 times more peanut protein than the placebo group (median, 1,710 vs 85 mg; $P = .011$). Mechanistic studies demonstrated a decrease in skin prick test wheal size ($P = .020$) and decreased basophil

responsiveness after stimulation with 10^{-2} $\mu\text{g/mL}$ ($P = .009$) and 10^{-3} $\mu\text{g/mL}$ ($P = .009$) of peanut. Peanut-specific IgE levels increased over the initial 4 months ($P = .002$) and then steadily decreased over the remaining 8 months ($P = .003$), whereas peanut-specific IgG4 levels increased during the 12 months ($P = .014$). Lastly, IL-5 levels decreased after 12 months ($P = .015$). No statistically significant changes were found in IL-13 levels, the percentage of regulatory T cells, or IL-10 and IFN- γ production.

Conclusion: Peanut SLIT is able to safely induce clinical desensitization in children with peanut allergy, with evidence of immunologic changes suggesting a significant change in the allergic response. Further study is required to determine whether continued peanut SLIT is able to induce long-term immune tolerance. (*J Allergy Clin Immunol* 2011;■■■:■■■-■■■.)

Key words: Peanut allergy, sublingual immunotherapy, desensitization, food allergy

From ^athe Department of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, and ^bthe Food Allergy Center at MGH, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston.

Supported by the National Institutes of Health: NCCAM R01-AT004435-03, 5T32-AI007062-32; the American Academy of Allergy, Asthma & Immunology/Food Allergy Initiative Howard Gittis Memorial 3rd Year/4th Year Fellowship/Instructor Award (J. A. B.); and the Wallace Research Foundation (WRF2010.01). Additional support for the project was provided by grant UL1RR024128 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and the NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.

Disclosure of potential conflict of interest: J. A. Bird has received research support from the American Academy of Allergy, Asthma & Immunology and the Food Allergy Initiative. M. Kulis has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). W. Shreffler has received research support from the NIAID. B. Vickery has received research support from the NIH/NIAID, Thrasher Research Fund, American Lung Association, and Cephalon. A. W. Burks has consulted for ActoGenix NV, Intelliject, McNeil Nutritionals, Novartis, and Schering-Plough; is a minority stockholder in Allertein and MastCell, Inc; is on an advisory board for Dannon Co Probiotics; is on an expert panel for Nutricia; has received research support from the NIH, Food Allergy and Anaphylaxis Network (FAAN), and Wallace Research Foundation; and is on the medical board of directors of FAAN. The rest of the authors have declared that they have no conflict of interest.

Received for publication September 13, 2010; revised November 30, 2010; accepted for publication December 2, 2010.

Reprint requests: A. Wesley Burks, MD, Department of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Box 2644, Durham, NC 27710.

E-mail: wesley.burks@duke.edu.

0091-6749/\$36.00

© 2011 American Academy of Allergy, Asthma & Immunology
doi:10.1016/j.jaci.2010.12.1083

Food allergy continues to be a significant public health problem in industrialized countries. The National Center for Health Statistics estimated that approximately 3.9% of US children in 2007 reported a food allergy in the past 12 months. This included an 18% increase in prevalence from 1997-2007.¹ Of all the foods implicated, peanut remains one of the most common and is considered one of the most severe, with the majority of food-related life-threatening and fatal allergic reactions caused by peanut ingestion.^{2,3} Of the more than 3 million Americans with a peanut or tree nut allergy,⁴ fewer than 20% will “outgrow” the allergy naturally.^{5,6} The current standard of care remains strict avoidance and the treatment of accidental ingestions with intramuscular epinephrine, antihistamines, or both.

A significant amount of research has focused on the use of immunotherapy for the treatment of food allergy. Although subcutaneous immunotherapy (SCIT) has been successfully used in the treatment of allergic rhinitis and asthma for many years, early attempts with SCIT for food allergy resulted in an unacceptably high rate of systemic reactions.⁷

In the past few years, several different types of therapy for food allergy have been studied, including oral immunotherapy (OIT), which involves ingesting milligrams to grams of allergen in the form of flour combined in a food vehicle. Ongoing research with OIT has shown interesting results, but this type of therapy needs much more study.⁸⁻¹¹ In contrast, sublingual immunotherapy (SLIT) involves the administration of small amounts (micrograms to milligrams) of allergen extract under the tongue. Although its

Abbreviations used

DBPCFC: Double-blind, placebo-controlled food challenge
 FoxP3: Forkhead box protein 3
 OIT: Oral immunotherapy
 SCIT: Subcutaneous immunotherapy
 SLIT: Sublingual immunotherapy
 SPT: Skin prick test
 Treg: Regulatory T

use has been limited in the United States, SLIT has been used commonly in Europe as an alternative to SCIT for allergic rhinitis. It offers a novel means of treatment for food allergy and seems well suited for several reasons.

First, oral Langerhans cells that take up antigen within the mouth have been shown to have tolerogenic properties, potentially accounting for the efficacy of aeroallergen SLIT.¹² Second, SLIT is easily administered, especially when compared with receiving injections, such as with SCIT, or ingesting large amounts of food, as with OIT. Finally, systemic reactions have been uncommon,¹³ which might be secondary to the relatively small doses used to achieve clinical efficacy.

We present the first study on the use of SLIT in the treatment of peanut allergy in children. The goal of our double-blind, placebo-controlled study was to evaluate the safety and efficacy of peanut SLIT after 12 months of therapy. In addition, we investigated whether any increase in the reaction threshold would be accompanied by immunologic changes indicative of a significant change in the allergic response.

METHODS**Study design**

The primary outcome of the study was to evaluate the reaction threshold to peanut ingestion after 12 months of peanut SLIT therapy compared with placebo. Food challenges to assess the primary end point were scheduled after 12 and 18 months of SLIT therapy. A planned interim analysis was performed after 18 months of enrollment to evaluate the primary end point and whether food challenges at later time points would be necessary to further assess the primary end point.

Secondary end points included the frequency and severity of side effects to dosing, as well as changes in several immunologic parameters, including peanut-specific IgE and IgG4 levels; basophil activation; skin test reactivity; levels of the cytokines IL-5, IL-13, IL-10, and IFN- γ ; and regulatory T (Treg) cells.

Subject recruitment

Subjects aged 1 to 11 years were recruited from the Duke University Medical Center Allergy and Immunology clinics and local referring physicians' offices. Subjects with a physician-documented clinical history of reaction to peanut within 60 minutes of ingestion and a CAP-FEIA peanut-specific IgE level of 7 kU/L or greater (Phadia AB, Uppsala, Sweden) were enrolled. Skin prick tests (SPTs) to peanut were not required for enrollment. Exclusion criteria included a history of severe anaphylaxis to peanut involving respiratory failure, hypotension, or other conditions necessitating care in the intensive care unit. The study was approved by Duke University's Institutional Review Board.

Randomization

Subjects were randomized 1:1 to receive either peanut SLIT or placebo. The primary investigators, clinical staff, subjects, and families remained blind

to the treatment, as well as all laboratory studies, during the 12-month study period. Laboratory staff were unblinded throughout the study. Subjects were unblinded after the double-blind, placebo-controlled food challenge (DBPCFC) performed at 12 months.

Peanut and placebo sublingual drops

Peanut and placebo sublingual drops were obtained from Greer Laboratories (Lenoir, NC). The treatment arm received crude peanut extract (1:20 wt/vol) fully dissolved in 0.2% phenol and 50% to 55% glycerinated saline to a maximum peanut protein concentration of 5000 μ g/mL. Ara h 2 content was conservatively estimated to be 6% of peanut protein concentration. The placebo group received a glycerinated saline solution plus phenol with caramel coloring. Dilutions were made with glycerinated saline, and doses were prescribed as 1 to 8 pumps (50 μ L per pump) of a 1:1000, 1:100, 1:10, or stock dilution of peanut SLIT or placebo (see Table E1 in this article's Online Repository at www.jacionline.org).

SLIT protocol

Subjects were instructed to continue a strict peanut-free diet for the duration of the study. Subjects were required to have an epinephrine autoinjector with them at all times. All observed dosing was performed on the Duke Clinical Research Unit, with ready access to epinephrine, diphenhydramine, and albuterol. Subjects were restricted from eating 15 minutes before and 30 minutes after dosing. Study drug was administered sublingually, held for 2 minutes, and then swallowed.

Dose escalation phase. During the initial visit, a single starting dose of 0.25 μ g of peanut protein (1 pump of 1:1000 dilution) or placebo was administered with a 2-hour observation period. Subjects then returned for 13 biweekly observed dose-escalation visits. Doses were increased by 25% to 100% until the maintenance dose of 2,000 μ g of peanut protein (8 pumps of 1:1 stock dilution) was reached. After each observed dose escalation, subjects continued the same dose daily at home for 2 weeks. Diaries were provided for families to document dosing and side effects.

Maintenance phase. The 2000- μ g maintenance dose was chosen based on the results of our pilot study of peanut SLIT (unpublished data) and on the limitations of the peanut SLIT concentration. With no immunologic changes detected in our pilot study with 45 μ g of peanut SLIT twice daily, we looked to significantly increase the dose for this study. With our peanut SLIT solution already maximally concentrated, we focused on the maximum amount of liquid a young child could be reasonably expected to hold sublingually. We decided on 8 pumps (400 μ L) of our fully concentrated peanut SLIT solution taken once daily, which resulted in our maintenance dose of 2000 μ g and was an approximately 22 times increase from the pilot study dose. After reaching the 2000- μ g maintenance dose, subjects continued daily maintenance dosing at home for approximately 6 months before returning for the DBPCFC.

DBPCFC

Subjects underwent a DBPCFC after completing the dose-escalation and maintenance phases. Before the food challenge, subjects were restricted from using antihistamines (short-acting antihistamines, 72 hours; long-acting antihistamines, 7 days) and β -agonists (12 hours). A study nurse or physician on the Duke Clinical Research Unit administered all challenges. The active portion of the DBPCFC consisted of 9 increasing doses of peanut protein in the form of peanut flour mixed in a vehicle food. Doses were given every 20 minutes up to a cumulative dose of 2500 mg of peanut protein. The placebo portion consisted of an equal amount of oat flour mixed in a vehicle food and given in the same increments. A coin flip determined the order of the peanut and placebo portions during the challenge day, and there was a minimum 2-hour observation period between portions. DBPCFC outcomes were reported as the cumulative dose ingested before the symptom-eliciting dose requiring treatment and discontinuation of the challenge. Symptoms observed in our study alone or in combination that resulted in challenge discontinuation included diffuse hives, severe nasal congestion, lip and tongue swelling, throat pain, coughing, moderate-to-severe abdominal pain, and vomiting.

TABLE I. Baseline subject characteristics

	Active group	Placebo group
No.	11	7
Age (y), median (range)	5.8 (2.8-10.5)	4.7 (1.6-7.4)
Sex	7 Male, 4 female	5 Male, 2 female
Race	10 White, 1 Asian	7 White
Asthma	5 (45%)	4 (57%)
Atopic dermatitis	9 (82%)	3 (43%)
Allergic rhinitis	8 (73%)	3 (43%)
Other food allergy	5 (45%)	1 (14%)
Median peanut-specific IgE (kU/L), range	33.5 (8.5-1,260)	31.1 (15-639)

Safety monitoring

All dose escalations and DBPCFCs were monitored by a study nurse or physician. Parents were instructed to monitor subjects for 2 hours after home dosing and document all dosing and side effects in home diaries. Side effects were grouped into skin, upper respiratory, chest, and abdominal symptoms. Timing relative to dosing and all treatments were also recorded. A food allergy action plan was provided to all families. Study personnel were available by telephone and pager at all times during the study.

Titration SPTs

Titration SPTs with peanut extract (Greer Laboratories) and controls were performed at baseline, 4 months, 8 months, and the day of the DBPCFC. The most dilute concentration of peanut extract (1:20, 1:200, 1:2,000, 1:20,000, and 1:200,000) resulting in a wheal of 5 mm or larger at baseline was followed for the duration of the study. Wheal size was calculated as the average of the largest diameter and the perpendicular midpoint diameter. Reaction to peanut was reported as the peanut wheal size minus the wheal size of the saline negative control.

Mechanistic studies

Basophil activation. Whole blood was obtained at baseline and the day of the DBPCFC and stimulated in the presence of IL-3 with several dilutions of crude peanut extract (10^0 , 10^{-1} , 10^{-2} , and 10^{-3} $\mu\text{g/mL}$), anti-IgE (1 $\mu\text{g/mL}$), and media alone.¹⁴ The crude peanut extract was prepared as previously described.¹⁵ After a 30-minute incubation, the reaction was stopped with EDTA, and antibodies were added. After another 30-minute incubation at 4°C, RBCs were lysed and leukocytes were fixed for flow cytometric analysis of activation markers. Basophils were identified as CD123⁺CD203c⁺lin⁻ (CD3, CD14, CD19, and CD41) events. Activation was assessed by CD63 (lysosomal-associated membrane protein-3) as the primary marker of activation.

Immunoglobulins. Serum was obtained at baseline, 4 months, 8 months, and the day of the DBPCFC. Peanut-specific IgE and IgG4 levels were measured with the Phadia AB ImmunoCAP 100 instrument per the manufacturer's instructions.

Cytokines. Heparinized blood was obtained at baseline, 4 months, 8 months, and the day of the DBPCFC. PBMCs were isolated by using Fico/Lite LymphoH density gradient sedimentation (Atlanta Biologicals, Lawrenceville, Ga) and suspended in 10% autologous plasma and culture media (RPMI-1640 with 2 mmol/L L-glutamine, 25 mmol/L HEPES buffer with 100 IU/mL penicillin, and 100 $\mu\text{g/mL}$ streptomycin; Mediatech, Manassas, Va). The PBMCs were plated in triplicate at a concentration of 4×10^5 cells per well with crude peanut extract (200 $\mu\text{g/mL}$), tetanus toxoid (5 $\mu\text{g/mL}$; EMD Biosciences, Darmstadt, Germany), concanavalin A, or media alone. Next, the PBMCs were incubated at 37°C in a 5% CO₂ humidified atmosphere for 72 hours. Finally, supernatants were collected, and the levels of 4 relevant cytokines, IL-5, IL-13, IL-10, and IFN- γ , were measured by means of ELISA (R&D Systems, Minneapolis, Minn). Cytokine levels in culture media controls were subtracted from crude peanut extract levels before reporting.

TABLE II. SLIT dosing safety

	Active group (n = 11)	Placebo group (n = 7)
Total doses	4182	2875
Reactions	480 (11.5%)	248 (8.6%)
Symptoms		
Oropharyngeal	391 (9.3%)	43 (1.5%)
Skin	25 (0.6%)	188 (6.5%)
Upper respiratory	59 (1.4%)	54 (1.9%)
Chest	2 (0.05%)	0
Abdominal	50 (1.2%)	53 (1.8%)
Treatment		
Antihistamine	11 (0.3%)	0
Epinephrine	0	0
Albuterol	1 (0.02%)	0

Treg cells. Isolated PBMCs from baseline and the day of the DBPCFC were plated with crude peanut extract (200 $\mu\text{g/mL}$) or media alone and incubated for 7 days. Cells were surface stained for CD4 and CD25 and then intracellularly stained for forkhead box protein 3 (FoxP3). Flow cytometry was performed, and CD4⁺CD25⁺ lymphocytes were gated for FoxP3 status by using FlowJo software (TreeStar, Ashland, Ore). Treg cells were reported as the percentage of CD4⁺ cells that were also CD25⁺ and FoxP3⁺.

Statistical analysis

To evaluate the primary end point, food challenge outcomes between the groups were compared with the Wilcoxon rank sum test (SAS 9.2; SAS Institute, Inc, Cary, NC) to control for outliers in our relatively small cohort. The Fisher exact test (SAS 9.2) was used to compare baseline characteristics of subjects receiving active treatment and placebo. With regard to secondary outcomes, to address the expected increase and then decrease in peanut-specific IgE levels over the length of the study, interval changes (0-4, 0-8, 0-12, 4-8, 4-12, and 8-12 months) were compared between the 2 groups by using a Bonferroni-corrected *P* value of less than .008 for significance. For SPT, basophil, IgG4, cytokine, and Treg cell analysis, the groups were compared at baseline and at 12 months by using a *P* value of less than .05 for significance. The Wilcoxon rank sum test was used for all secondary outcome group comparisons.

RESULTS

Study population

At the time of the interim analysis, 18 subjects completed 12 months of dosing and the DBPCFC with no dropouts. Eleven of these subjects were randomized to peanut SLIT, whereas only 7 subjects were randomized to placebo. This skewing from the 1:1 randomization scheme occurred because of 2 reasons. First, the timing of our interim analysis was based on the first subject reaching the 18-month time point and not on the number of subjects in each cohort. Second, subjects were not challenged in the same order that they were enrolled and randomized. There were no statistical differences between the groups at baseline (Table I). The median age at enrollment was 5.2 years (range, 1.6-10.5 years). Five (28%) subjects had additional food allergies, most commonly egg allergy. Most subjects had a history of atopic dermatitis (67%), asthma (50%), or allergic rhinitis (61%).

Dosing safety

Compliance was similar in both groups, with subjects receiving peanut SLIT taking 95.4% of doses and those receiving placebo taking 93.8% of doses. Symptoms were reported with 11.5% of peanut doses and 8.6% of placebo doses (Table II). The majority




FIG 1. DBPCFC after 12 months of SLIT or placebo. **A**, When challenged with 2,500 mg of peanut protein, subjects receiving peanut SLIT demonstrate an increased reaction threshold. Boxes represent interquartile ranges with lines at the median. Bars represent minimum and maximum values. * $P = .011$. **B**, Association of DBPCFC outcomes with peanut-specific IgE from the day of challenge for active treatment. ** $P = .043$.

of reactions for those receiving peanut were transient oropharyngeal itching (9.3%), whereas skin itching was most common for those receiving placebo (6.5%). Of the 4182 active peanut doses, 11 (0.26%) home doses required treatment with an antihistamine. One (0.02%) home dose also required albuterol for mild wheezing. No placebo doses required antihistamine or albuterol treatment, and no epinephrine was required for any doses during the study. The symptoms that necessitated treatment included lip swelling, throat itching, finger swelling, itchy skin, and 1 episode of wheezing.

DBPCFC

At the time of the interim analysis, 18 enrolled subjects completed the 2500-mg peanut protein DBPCFC after 12 months of SLIT (Fig 1, A). The 11 subjects randomized to active peanut SLIT treatment safely ingested a median cumulative dose of 1,710 mg of peanut protein compared with the 7 subjects receiving placebo, who ingested a median cumulative dose of 85 mg ($P = .011$). A modest but significant association ($r^2 = 0.38$, $P = .043$) was found between the outcome of the DBPCFC and the level of peanut-specific IgE obtained on the day of challenge (Fig 1, B). No association was found between DBPCFC outcome and the peanut SPT response, peanut-specific IgG4 level, or basophil responsiveness from the day of challenge.

Titrated SPTs

Responses of titrated SPTs to peanut were not statistically different between the groups at baseline, with a median wheal size of 9 mm (range, 4.5–16 mm) in the active group and 5.5 mm (range, 2.5–9 mm) in the placebo group. After 12 months, SPT responses in the active treatment group were significantly smaller than in the placebo group ($P = .020$), with a median wheal size of 4 mm (range, 0–11 mm) in the active treatment group and 11.5 mm (range, 3.5–21 mm) in the placebo group (Fig 2). The increase in median wheal size for the placebo group from baseline to 12 months was not significant.

Basophil activation

Six subjects receiving treatment and 5 receiving placebo had both baseline and 12-month measurements available for analysis of basophil activation (Fig 3). There was no statistical difference




FIG 2. Titrated SPTs at baseline and after 12 months of peanut SLIT or placebo. After 12 months, peanut SLIT results in a decreased wheal size to peanut SPTs. Boxes represent interquartile ranges with lines at the median. Bars represent minimum and maximum values. * $P = .020$.

in the percentage of CD63⁺ basophils at baseline between active treatment and placebo when stimulated with 10^0 , 10^{-1} , 10^{-2} , and 10^{-3} $\mu\text{g/mL}$ crude peanut extract. After 12 months, a significantly lower percentage of CD63⁺ basophils was found in the active treatment group compared with the placebo group when stimulated with 10^{-2} and 10^{-3} $\mu\text{g/mL}$ crude peanut extract ($P = .009$ and $P = .009$, respectively). No difference was seen between the groups after stimulation with 10^0 and 10^{-1} $\mu\text{g/mL}$ crude peanut extract.

Immunoglobulins

Baseline peanut-specific IgE levels were not statistically different between the groups, with a median level of 33.5 kU/L (range, 8.5–1260 kU/L) in the active treatment group and 31.1 kU/L (range, 15–639 kU/L) in the placebo group. During the initial 4 months of SLIT, peanut-specific IgE levels in the active treatment group increased significantly compared with those in the placebo group ($P = .002$) up to a median level of 118.5 kU/L. Over the subsequent 8 months of the study, peanut-specific IgE levels in the active treatment group decreased significantly compared with those in the placebo group ($P = .003$) to a median level of 31.4 kU/L (Fig 4, A). There was no difference in peanut-specific IgG4 levels between the groups at baseline, with levels of 0.3 mg/L (range, 0.1–0.6 mg/L) and 0.2 mg/L (range, 0.05–0.55 mg/L) in the active treatment and placebo groups, respectively. After 12 months, peanut-specific IgG4 levels were




FIG 3. Percentage of CD63⁺ activated basophils at baseline and after 12 months of peanut SLIT or placebo. After 12 months, peanut SLIT results in a decreased percentage of activated basophils when stimulated with 10⁻² and 10⁻³ μ g/mL crude peanut extract. *Open boxes*, Baseline; *hatched boxes*, 12 months. *Boxes* represent interquartile ranges with lines at the median. *Bars* represent minimum and maximum values. * P = .009. ** P = .009.

significantly higher in the active treatment group at 1.12 mg/L (range, 0.1-22 mg/L) compared with those in the placebo group (P = .014), which remained virtually unchanged at 0.09 mg/L (range, 0.04-0.94 mg/L; Fig 4, B).

Cytokine analysis

Baseline IL-5 levels in the active treatment group (308.6 pg/mL; range, 32.4-1145.9 pg/mL) and placebo group (569.9 pg/mL; range, 45.9-1286.1 pg/mL) were not statistically different. After 12 months, IL-5 levels were significantly lower in the active treatment group (79 pg/mL; range, 4-881.3 pg/mL) compared with those in the placebo group (368.9 pg/mL; range, 104.9-1068.5 pg/mL; P = .015; Fig 5, A). IL-13 levels in the active treatment group decreased from a median of 147.1 pg/mL (range, 0-374.8 pg/mL) at baseline to 62.1 pg/mL (range, 0-221.7 pg/mL) after 12 months. However, this level was not significant compared with that in the placebo group (P = .06), which also decreased from a median baseline of 369.6 pg/mL (range, 0-915.3 pg/mL) to 149.55 pg/mL (range, 71.1-453.3 pg/mL) after 12 months (Fig 5, B). No differences between the 2 groups were found in IL-10 or IFN- γ levels at baseline or at 12 months (data not shown).

Treg cell analysis

Quantitative analysis of Treg cells demonstrated no statistical difference at baseline between the active treatment (median, 2.98%; range, 1.56%-4.36%) and placebo (median, 2.59%; range, 1.76%-4.7%) groups. After 12 months, an increased percentage of Treg cells was seen in the active treatment group (median, 7.68%; range, 2.55%-16.61%) compared with the placebo group (median, 2.69%; range, 0.43%-11.78%), but this result did not reach significance (P = .145, Fig 6).

DISCUSSION

Despite significant ongoing research, no treatments for peanut allergy are available. The standard of care remains avoidance. SLIT is a novel and possibly safer approach to desensitization and might have the potential to induce long-term oral tolerance. In this first double-blind, placebo-controlled study of peanut SLIT, subjects underwent 6 months of build-up dosing followed by 6 months of maintenance dosing. Subjects receiving peanut SLIT had a significant increase in reaction threshold after safely ingesting a median cumulative dose of 1710 mg of peanut protein (equivalent to 6-7 peanuts). This was significantly more than

those receiving placebo, who only safely ingested a median cumulative dose of 85 mg (<1 peanut). This level of desensitization is clinically significant in that it likely represents protection from accidental ingestions of peanut that are often caused by the ingestion of less than 100 mg of peanut.¹⁶ To investigate possible predictors of food challenge outcomes, we correlated the results of DBPCFCs with immunologic data obtained on the day of challenge, including SPT responses, peanut-specific IgE and IgG4 levels, and basophil stimulation assay results. An association between DBPCFCs and a lower peanut-specific IgE level but not SPT responses, IgG4 levels, or basophil numbers was found in the treatment group. This association is likely modest at best because the r^2 value of 0.38 indicates that factors in addition to allergen-specific IgE are involved.

Subjects receiving peanut SLIT displayed immunologic changes similar to those seen in patients receiving SCIT for environmental allergies. Aeroallergen SCIT has suppressive effects on mast cells and basophils.¹⁷ We found a significant decrease in SPT wheal diameter in the active treatment group after the 12-month study period. This finding is indicative of a decrease in mast cell reactivity. Basophil reactivity was also diminished after 12 months of peanut SLIT, as indicated by the significantly lower percentage of CD63⁺ activated basophils after stimulation with peanut extract.

With respect to humoral changes, peanut-specific IgE levels increased significantly in the active treatment group during the first 4 months to a median of almost 4 times the baseline level. No significant change in peanut-specific IgE levels was noted in the placebo group. Over the remaining 8 months, peanut-specific IgE levels in the active treatment group decreased significantly compared with those in the placebo group, which remained stable. On the other hand, levels of peanut-specific IgG4, which is thought to block the binding of allergen to effector cells,¹⁸ were significantly increased compared with those in subjects receiving placebo, which remained unchanged.

The effects of immunotherapy on mast cells, basophils, and B cells are thought to be a result of the downregulation of IL-4, IL-5, and IL-13, as well as the increased production of IL-10 and TGF- β by Treg cells.^{17,19} Treg cells are also thought to suppress the effects of T_H2 cells.¹⁹ This central role of Treg cells is supported by a recent study of grass pollen SLIT by Allam et al,²⁰ which demonstrated increased production of IL-10 and TGF- β by oral Langerhans cells and an increased number of IL-10 and TGF- β -producing Treg cells after SLIT therapy. We did not see an increase in IL-10 production with peanut SLIT; however, we were able to show an increased percentage of Treg cells, which might have reached significance with a larger sample size. The Treg cells reported by Allam et al are hypothesized to be IL-10- and TGF- β -producing type 1 Treg cells or T_H3 cells. A possible explanation for our discrepancy in IL-10 production is that in contrast to grass pollen SLIT, peanut SLIT might preferentially induce naturally occurring FoxP3⁺ Treg cells, which are thought to mediate their effects less through secreted cytokines and more through direct cell contact. Although we were unable to define the role of Treg cells in peanut SLIT, our results clearly show a downregulation of the T_H2 response, as represented by a decrease in IL-5 production after 12 months of peanut SLIT.

Production of another T_H2 cytokine, IL-13, also decreased after 12 months of peanut SLIT, but this was not significant because a parallel decrease was seen in the placebo group during this time period. We are unaware of any studies demonstrating decreases




FIG 4. Levels of peanut-specific immunoglobulins at baseline and after 12 months of peanut SLIT or placebo. **A**, After 12 months, peanut SLIT results in an increase in peanut-specific IgE levels over 4 months followed by a decrease over the subsequent 8 months. * $P = .002$. ** $P = .003$. **B**, After 12 months, peanut results in an increase in peanut IgG4 levels. *** $P = .014$. Boxes represent interquartile ranges with lines at the median. Bars represent minimum and maximum values.




FIG 5. Cytokine secretion after stimulation with crude peanut extract at baseline and after 12 months of peanut SLIT or placebo. **A**, After 12 months, peanut SLIT results in a decrease in IL-5 secretion. * $P = .015$. **B**, After 12 months, a decrease in IL-13 secretion was found in both the peanut SLIT and placebo groups. Boxes represent interquartile ranges with lines at the median. Bars represent minimum and maximum values.

in IL-13 production during peanut avoidance and thus believe that this result is more likely an artifact of our small sample size rather than a true phenomenon.

Lastly, we measured the production of a representative T_H1 cytokine, IFN- γ , but did not see an increase that would indicate that peanut SLIT causes a shift from a T_H2 response toward a T_H1 response. The decrease in IL-5 production detected in our study is in contrast to recently published results by our group on OIT for peanut allergy, which showed an increase in IL-5 production after therapy.²¹ In another recently published study on peanut OIT, Blumchen et al²² also demonstrated decreased levels of IL-5 after therapy. We suspect that the discrepant results found in our OIT study might have been a result of the relatively low levels of IL-5 measured. These low levels combined with a sample size of 5 might have amplified typical biologic variation and resulted in the discrepancy. Another possible explanation could be that the different methodology needed to measure the low levels might have introduced more error. We believe that the results of our study, which are in agreement with those of Blumchen et al, are more plausible because they support the hypothesis of a downregulation of the T_H2 response by immunotherapy.

Few studies have examined SLIT for the treatment of food allergy. There have been case reports on its effective use for the treatment of kiwi allergy^{23,24} and a trial lacking clinical benefit in peach allergy.²⁵ In 2005, Enriquez et al²⁶ described a double-blind




FIG 6. Percentage of Treg cells at baseline and after 12 months of peanut SLIT or placebo. Although an increase in Treg cells was seen after 12 months of peanut SLIT, this did not reach significance. Boxes represent interquartile ranges with lines at the median. Bars represent the minimum and maximum values.

study of SLIT in the treatment of hazelnut allergy. Subjects receiving active treatment tolerated a significantly larger amount of hazelnut, but the results were difficult to extrapolate to peanut allergy because half of the subjects had oral allergy syndrome, a limited form of oral pruritus caused by epitopes cross-reactive with pollens rather than IgE-mediated food allergy.

Although reports on SLIT for food allergy have been limited, SLIT has been used extensively in Europe as an alternative to

SCIT for the treatment of allergic rhinitis and asthma. A 2006 American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology joint task force report on aeroallergen SLIT found that two thirds of studies reported an improvement in symptom scores.¹³ Although an increase in allergen-specific IgG4 levels was commonly reported, changes in allergen-specific IgE levels were rare, and reported changes in cytokine levels were inconsistent. The report also showed that regarding the safety of aeroallergen SLIT, local oropharyngeal itching was the most common side effect reported. Similarly, oropharyngeal itching was the most commonly reported side effect in our study, with subjects receiving active treatment reporting transient oropharyngeal itching with 9.3% of doses. Systemic reactions have been quite uncommon in aeroallergen SLIT.¹³ In our study only 0.3% of active treatment doses required treatment with an antihistamine. Only 1 (0.02%) dose required treatment with a β -agonist. Most importantly, epinephrine was not required for any SLIT dosing.

There are several notable limitations to our study. We did not include an entry food challenge and were therefore unable to determine individual changes in reaction threshold. Future studies will incorporate an entry challenge. Nevertheless, a 20-fold greater amount of ingested peanut protein in the active treatment group compared with the placebo group indicates a high likelihood of clinical efficacy. An ongoing double-blind, placebo-controlled randomized trial of peanut SLIT through the Consortium of Food Allergy Research (ClinicalTrials.gov no. NCT00580606) involves a larger number of subjects from multiple centers and should provide further insight into the efficacy of SLIT. Regarding the induction of oral tolerance, we have not examined the long-term effects of peanut SLIT after stopping the therapy. Changes in peanut-specific IgE and IgG4 levels, as well as the decrease in IL-5 levels, are promising and might suggest the beginning of longer-term tolerance to peanut, but continued study is needed.

In summary, our study shows that peanut-specific SLIT can be a safe and effective form of immunotherapy for children with peanut allergy. SLIT induces significant desensitization after 12 months of therapy. Immunologic data demonstrate a diminished allergic response in mast cells and basophils, decreasing peanut-specific IgE and increasing peanut-specific IgG4 levels, and a decrease in IL-5 production.

We thank Xiaohong Yue, Hua-Mei Zhang, and Nikolas Kamilaris of the Burks Laboratory for their assistance with the laboratory assays; Alison Edie, FNP, and Jane Hainline, RN, for assistance with dosing and follow-up visits; and Henry Beresford, Duke University School of Nursing, for development and maintenance of the patient database. We also thank the Duke Clinical Research Unit for providing the clinic space and staff support necessary to conduct our study.

Key messages

- Twelve months of peanut SLIT induces clinical desensitization.
- Clinical desensitization is accompanied by significant changes in basophil activation, SPT responses, and peanut-specific IgE, peanut-specific IgG4, and IL-5 levels.
- Further study is required to assess long-term clinical tolerance.

REFERENCES

1. Branum AM, Lukacs SL. Food allergy among U.S. children: trends in prevalence and hospitalizations. *NCHS Data Brief* 2008;(10):1-8.
2. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. *J Allergy Clin Immunol* 2001;107:191-3.
3. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. *J Allergy Clin Immunol* 2007;119:1016-8.
4. Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J Allergy Clin Immunol* 2010;125:1322-6.
5. Hourihane JO, Roberts SA, Warner JO. Resolution of peanut allergy: case-control study. *BMJ* 1998;316:1271-5.
6. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. *J Allergy Clin Immunol* 2001;107:367-74.
7. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. *J Allergy Clin Immunol* 1997;99:744-51.
8. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. *J Allergy Clin Immunol* 2009;124:292-300, e1-97.
9. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. *Allergy* 2009;64:1218-20.
10. Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, De Pasquale T, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. *Aliment Pharmacol Ther* 2003;17:459-65.
11. Bauer A, Ekanayake Mudiyansele S, Wigger-Alberti W, Elsner P. Oral rush desensitization to milk. *Allergy* 1999;54:894-5.
12. Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B, Bieber T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. *J Allergy Clin Immunol* 2008;121:368-74, e1.
13. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. *J Allergy Clin Immunol* 2006;117:1021-35.
14. Wanich N, Nowak-Wegrzyn A, Sampson HA, Shreffler WG. Allergen-specific basophil suppression associated with clinical tolerance in patients with milk allergy. *J Allergy Clin Immunol* 2009;123:789-94, e20.
15. Pons L, Ponnappan U, Hall RA, Simpson P, Cockrell G, West CM, et al. Soy immunotherapy for peanut-allergic mice: modulation of the peanut-allergic response. *J Allergy Clin Immunol* 2004;114:915-21.
16. Taylor SL, Moneret-Vautrin DA, Crevel RW, Sheffield D, Morisset M, Dumont P, et al. Threshold dose for peanut: risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals. *Food Chem Toxicol* 2010;48:814-9.
17. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. *J Allergy Clin Immunol* 2007;119:780-91.
18. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. *J Allergy Clin Immunol* 2004;113:1025-35.
19. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. *J Allergy Clin Immunol* 2005;116:961-9.
20. Allam JP, Wurtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF- β 1 and IL-10-producing properties. *J Allergy Clin Immunol* 2010;126:638-45, e1.
21. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. *J Allergy Clin Immunol* 2009;124:292-300, e1-97.
22. Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschoner J, de Oliveira LC, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. *J Allergy Clin Immunol* 2010;126:83-91, e1.
23. Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. *J Allergy Clin Immunol* 2003;111:1406-9.
24. Kerzl R, Simonowa A, Ring J, Ollert M, Mempel M. Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. *J Allergy Clin Immunol* 2007;119:507-8.
25. Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE, Gonzalez-Mancebo E, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. *Allergy* 2009;64:876-83.
26. Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. *J Allergy Clin Immunol* 2005;116:1073-9.

TABLE E1. Peanut SLIT dosing schedule

Visit no.	Dilution	Pumps	Protein (μg)	Ara h 2 (μg)
1	1:1000	1	0.25	0.015
2	1:1000	5	1.25	0.075
3	1:100	1	2.5	0.15
4	1:100	2	5	0.3
5	1:100	4	10	0.6
6	1:100	8	20	1.2
7	1:10	1	25	1.5
8	1:10	2	50	3
9	1:10	4	100	6
10	1:10	8	200	12
11	1:1	1	250	15
12	1:1	2	500	30
13	1:1	4	1,000	60
14	1:1	8	2,000	120